Index to Volume 1

Author Index

Abraham, E. P., 99
Acar, J. F., 825
Alford, R. H., 175
Alkan, M. L., 832
Allo, M., 386
Amaral, L., 813
Armengaud, M., 132
Armengaud, M. J., 132
Armstrong, J., 386
Arnon, S. S., 614, 693
Ashdown, L. R., 891
Atkinson, B. A., 797
Bach, V., 170
Baine, W. B., 912
Barbaro, S., 858
Bartlett, J. G., 278, 291, 370, 379, 398, 530, 727
Barza, M., 106
Beachey, E. H., 832
Billiard, B. S., 152
Birnbaum, J., 73
Bjornson, A. B., 347
Bjornson, H. S., 347
Bonventre, P. F., 663
Booth, S. J., 325
Bouanchaud, D. H., 825
Brown, K. R., 228
Brown, L. W., 625
Brown, S. T., 183
Browne, R., 386
Busch, D. F., 113
Cama, L. D., 64
Chang, T., 370
Cherubin, C. E., 134
Cheung, K. S., 976
Chin, J., 614, 693
Chinn, N. M., 630
Chowning, W. M., 540
Christensen, B. G., 64
Citron, D. M., 113
Clyde, W. A., Jr., 1007
Coligan, J. E., 904
Collier, A. M., 1007
Condon, R. E., 302
Cornett, J. B., 787
Couchonnal, G., 127
Dabydeen, H., 821
Daneo-Moore, L., 787
Daniel, D., 210
Davies, J., 23
Davies, R. O., 90
Davis, C., 210
Delamar, D. K., 195
Del Bene, V. E., 195
Denny, F. W., 1007
Dillingham, M., 206
Dillon, H. C., Jr., 935
Dworzack, D. L., 127
Ebright, J., 386
Eickhoff, T. C., 158
Eisenstein, B. I., 822
Eklund, M. W., 630
Ell, S. R., 563
Evans, D. A., 2
Ezrow, L., 821
Fass, R. J., 165
Fekety, R., 386
Feldman, R. A., 612
Fernald, G. W., 1007
Field, M., 918
Fierer, J., 210
File, T. M., 165
Fillastre, J. P., 118, 726
Finegold, S. M., 113, 218, 248
Finland, M., 4
Fitzwilliam, J. F., 976
Fossedal, E. N., 302
Frank, M. M., 483
Freimer, E. H., 152
Fridovich, I., 357
Gardner, I. D., 885
Gear, J. H. S., 571
Getson, A. J., 228
Godin, M., 118, 726
Gorbach, S. L., 106, 291
Gould, A. L., 228
Grassi, G. G., 852
Greenwood, D., 807
Gross, K. C., 955
Gunn, R. A., 642, 720, 722
Hadley, K., 202
Hamilton, J. D., 976
Handschin, H., 845
Harms, J. L., 127
Hassan, H. M., 357
Hatheway, C. L., 647
Henderson, F. W., 1007
Hendlin, D., 73
Hentges, D. J., 668
Hinthorn, D. R., 127
Ho, M., 189
Hodges, G. R., 127
Hofstad, T., 342
Hoke, C. H., Jr., 946
Holmes, G. I., 90
Hopkins, J. A., 946
Horstmann, D. M., 502
Houser, H. B., 899
Humbert, G., 118, 726
Johnson, J. L., 325
Jones, P. K., 927
Joris, I., 880
Kasper, D. L., 246, 263, 278, 291
Kass, E. H., 1, 2
Kaufmann, A. F., 912
Keusch, G. T., 517
Kirby, B. D., 113, 218
Kitzis, M. D., 132, 825
Kradolfer, F., 862
Krause, R. M., 904
Krieger, A. G., 955
Lang, D. J., 976
Lankford, L. L., 729
Ledger, W. J., 199
Leroy, A., 118, 726
Lewis, G. E., Jr., 689
Liu, C., 127
Lorian, V., 797
Louie, T. J., 291
Lutwick, L. I., 895
Lyon, J. A., 189
Maca, H. W., 912
Majno, G., 880
Mansheim, B. J., 263, 291
Markham, R. B., 567
Martin, C. M., 90, 228
Martinetto, P., 858
Massip, P., 132
Mayer, L., 55
McCloskey, R. V., 224
Meiklejohn, G., 946
Menge, E.-B., 845
Metzger, J. F., 689
Midura, T. F., 652, 693
Miller, A. K., 73
Montgomerie, J. Z., 736, 754
Mortimer, E. A., Jr., 927
Mostow, S. R., 946
Murphy, B. R., 413
Mychajlonka, M., 787
Nair, S. R., 134
Nelson, J. D., 698
Neu, H. C., 144, 233
Newman, M. G., 313
Nichols, R. L., 302
Ofek, I., 832
O'Keefe, J. P., 106
Onderdonk, A. B., 263, 278, 291, 370, 398
Ormsbee, R. A., 559
Pasculle, A. W., 189
Paterson, P. Y., 468
Pazin, G. J., 189
Perine, P. L., 183
Perkins, R. L., 165
Peterson, D. R., 630
Pinsky, R. L., 895
Pittman, M., 401, 897
Plouffe, J. F., 165
Polk, B. F., 278, 567
Prior, R. B., 165

Purchase, H. G., 600
Rambo, W. M., 195
Rasheed, J. K., 912
Reynolds, G., 183
Ribner, B. S., 152
Ricci, F. M., 228
Richman, D. D., 413
Richmond, M. H., 30
Rifkin, G., 386
Robbie, M., 202
Roberts, R. B., 955
Rogers, J. D., 90
Ruswinkle, L. J., 64
Saceanu, C., 821
Sandberg, T., 838
Santiano, M., 858
Sapico, F. L., 754
Schiller, C. M., 674
Schrogie, J. J., 90
Schurman, D. J., 206
Schwartz, S. N., 189
Sharon, N., 832
Shockman, G. D., 787
Shortridge, K. F., 885
Siegel, M. S., 183
Silva, J., 386
Simpson, L. L., 656
Skeggs, H., 90
Slama, T. G., 165
Smith, D., 199
Smith, J. W., 302
Smith, L. DS., 254, 637
Sonnenwirth, A. C., 337
Stapley, E. O., 73
Stenqvist, K., 838
Stuart-Harris, C. H., 592
Sugiyama, H., 683
Sutker, W. L., 729
Sutter, V. L., 218
Svanborg-Edén, C., 838
Sveen, K., 342
Sweet, R. L., 202
Tally, F. P., 106
Tan, E. M., 977
Taylor, N. S., 370, 379, 727
Terranova, W. A., 722
Thadepalli, H., 170
Thompson, S. E., 183
Thornsberry, C., 183
Tipper, D. J., 39
Tomasz, A., 434
Tompsett, R., 729
Toshniwal, R., 386
Tran, V. T., 132
Traub, S. L., 726
Trousseau, A., 1016
Valtz, A., 858
van Ermengem, E., 701
Van Tassell, R. L., 325
Van Winzum, C., 118, 726
Viano, I., 858
Vosbeck, K., 845
Walden, R., 674
Wallick, H., 73
Wannamaker, L. W., 967
Warner, J. F., 165
Washington, J. A. II, 781
Webb, D., 170
Weinstein, M., 134
Weinstein, M. P., 158
Wilkins, T. D., 325
Wilson, L. B., 540
Woodruff, H. B., 73
Yeh, K. C., 90
Young, F. E., 55
Zak, O., 845, 862

Subject Index

Adhesion, of *E. coli* to human cells in vitro, effects of subminimal inhibitory concentrations of antibiotics, 832, 838, 845
Aminoglycoside and β-lactam antibiotics, suppression of bacterial adherence by subminimal inhibitory concentrations, 832
Ampicillin
  effects of subminimal inhibitory concentrations on attachment of *E. coli* to human uroepithelial cells in vitro, 838
  or mecillinam, Enterobacteriaceae grown in presence of subminimal inhibitory concentration, effect of serum and blood, 797
Anaerobic bacteria
  causing foot infections in diabetics, efficacy of cefoxitin treatment, 210
  comparison of efficacies of cefoxitin and parenterally administered cephalosporins, 218
  efficacy of cefoxitin treatment in infections, 113
  essential factor in action of metronidazole against *E. coli*, 291
  experimental animal models of intraabdominal sepsis and wound infections, 291
  human antibody response, summary of current data, 337
  review of taxonomy, enzymes, clinical relevance, 248
  role in periodontal infections, 313
  virulence factors
    overview, 246
    summary of symposium, 398
    symposium, 245–400
Antibacterial drugs, interactions below the MIC, 807
Antibiotic-inactivating enzymes, of bacteria grown in subminimal inhibitory concentrations of antibiotics, 852
Antibiotics
  activity range, and ratio of MIC to minimal antibiotic concentration, 821
  β-lactam
    mode of action, review of biochemical data, 39
    resistance of bacteria and development of β-lactamase-resistant drugs, 30
  emergence of resistant organisms in hospitals (1935–1975), 4
  genetic determinants of microbial resistance, 55
  mechanisms of bacterial resistance, 23
  parenteral, alone or combined, for treatment of intraabdominal sepsis, 302
  resistant to microbial inactivation, design of new drugs, 64
  subminimal inhibitory concentrations
    effects on adhesion of *E. coli* to human cells in vitro, 832, 838, 845
    effects on bacteria and host, 781
    symposium, 780–879
Antibodies
  human, to anaerobic bacteria, summary of current data, 337
  preventing adherence of *B. pertussis* to cilia of respiratory epithelium, first line of defense in whooping cough, 401
  to streptococcal carbohydrates, substitutes for myeloma proteins in studies of antibody molecular structure, review, 904
Antigens
  of *B. pertussis*, characterization, role in whooping cough, 401
  surface
    of *B fragilis*, as virulence factors in infection, 278
    of *B. melaninogenicus*, immunochemical characterization, 263
Antitoxin, against "pertussis toxin," second line of defense in whooping cough, 401
Arthritis, rheumatoid, possible role of Epstein-Barr virus, 997
Attenuation, viral, in animals and humans, association with temperature-sensitive phenotype, implications for live virus vaccines, 413
Autoimmune diseases, of animals and humans, history, current data, new perspectives, 468
Autolysis, as mode of action of β-lactam antibiotics, 434
Babesiosis, and Rocky Mountain spotted fever, comment on work of Wilson and Chowning, 895
Bacteriophages, of *Bacteroides*, characterization and use in identification of bacterial strains, 325
Bacteroides fragilis
  ability to reduce chloramphenicol to biologically inactive aryl amine derivative, 291
  greater activity of cefoxitin than of parenterally administered cephalosporins, 218
  lipopolysaccharide, chemotactic for polymorphonuclear leukocytes, 342
  opsonization by normal human serum, role of immunoglobulin and alternative complement pathway components, 347
  reduced levels of cephalothin and cefoxitin at infected sites, 106
  surface antigens, as virulence factors in infection, 278
Bacteroides melaninogenicus
  role in periodontal infections, 313
  surface antigens, immunochemical characterization, 263
Bacteroides species
  human antibody response, summary of current data, 337
  specific bacteriophages, characterization and use in identification of bacterial strains, 325
Bacteroides thetaiotaomicron, opsonization by normal human serum, role of immunoglobulin and alternative complement pathway components, 347
β-Lactam and aminoglycoside antibiotics, suppression of bacterial adherence by subminimal inhibitory concentrations, 832
β-Lactam antibiotics
  insensitive to hydrolysis by β-lactamases, for use against resistant bacteria, 30
  mode of action, review of biochemical data, 39
  possible modes of action, review, 434
β-Lactamases, development of β-lactam antibiotics insensitive to hydrolysis, 30
Billroth, Theodor, and *Penicillium*, history, 880
Bordetella pertussis, single antigen ("pertussis toxin") as cause of harmful effects and prolonged immunity of whooping cough, 401
Botulinal toxin
  absorption from gastrointestinal tract, 663

characterization, mechanism of action, 656
mouse neutralization test, 647
Botulism
classic description (reprint of van Ermengem, 1897), 701
comment on classic description by van Ermengem, 720
food-borne and infant, in U.S. (1977), 722
infant
absorption of toxin from gastrointestinal tract, 663
age of onset, 642
animal models, 683
characteristics and occurrence of *C. botulinum*, 637
clinical spectrum, 614
current perspectives, research priorities, 698
differential diagnosis, 625
epidemiology in U.S. (1975–1978), 642
germination of organism and toxin production in infant intestine, 614
in California
food and environmental aspects, 693
laboratory aspects, 652
laboratory procedures for suspected cases, 647
mechanism of toxin action, 656
month of onset, 642
possible treatment with human-derived immune globulins, 689
presence of *C. botulinum* in honey, soil, vacuum cleaner dust, 652, 693
relation to sudden infant death syndrome, 614, 625, 630
role of intestinal flora in resistance, 668
significance of transport and absorption processes in developing infant intestine, 674
seminar, 611–700
toxin, botulinal, mouse neutralization test, 647
treatment with human-derived immune globulins, 689
Cefoxitin
activity against anaerobic bacteria, comparison with parenterally administered cephalosporins, 218
administered im, appropriate usage, efficacy, side effects, 224
effective against anaerobic or mixed anaerobic-aerobic infections, 113
in bacterial endocarditis, mixed results, 170
in foot infections due to mixed anaerobic flora in diabetics, 210
in infections due to endemic, multiply resistant gram-negative rods, 175
in infections in orthopedic patients, 206
in infections in surgical patients, 195
in obstetric and gynecologic infections, 199, 202
in respiratory tract and other acute bacterial infections, 158
in significant bacterial infections in adults, 152
in skin, soft tissue, and bone infections, 165
in uncomplicated gonococcal urethritis, comparison with penicillin, 183
microbiological studies, 73
overview of clinical studies in U.S., 233
penetration into canine cerebrospinal fluid, effect of *S. aureus* meningitis, 132
penetration into human cerebrospinal fluid, 127, 134
pharmacokinetics
and pharmacology, comparison with cephalosporins, 90
error in published equation for half-lives, 726
in normal subjects and patients with renal insufficiency, 118, 726
reduced levels at *B. fragilis*-infected sites due to inactivation and decreased penetration, 106
role of 7-α-methoxy group in stability in presence of β-lactamase, 64, 73
safety, analysis by three methods and comparison with cephalothin by new method, 228
vs. cephalothin, efficacy and safety, review, 144
Cell-surface receptors, specific, pathogenetic and therapeutic implications in infectious diseases, 517
Central nervous system, immunologically mediated diseases, history, current data, new perspectives, 468
Cephalosporins
early history, 99
parenterally administered, activity against anaerobic bacteria, comparison with cefoxitin, 218
pharmacokinetics and pharmacology, comparison with cefoxitin, 90
Cephalothin
reduced levels at *B. fragilis*-infected sites due to inactivation and decreased penetration, 106
vs. cefoxitin, review of efficacy and safety, 144
Cephamycins
microbiological studies, 73
role of 7-α-methoxy group in stability in presence of β-lactamase, 64, 73
Cerebrospinal fluid
canine, penetration of cefoxitin, effect of *S. aureus* meningitis, 132
human, penetration of cefoxitin, 127, 134
Chemotaxis, positive, for polymorphonuclear leukocytes, exerted by *B. fragilis* lipopolysaccharide, 342
Chikungunya fever, 571
Chloramphenicol
effects of subminimal inhibitory concentrations on attachment of *E. coli* to human uroepithelial cells in vitro, 838
reduction to biologically inactive aryl amine derivative by *B. fragilis*, 291
Cholera toxin, nature of binding to specific membrane receptors, comparison with binding of shigella toxin, 517
Ciliary activity, in ferret tracheal organ culture, effect of five wild-type influenza A viruses, possible relation to viral virulence, 946
Clostridium botulinum
characteristics, distribution, frequency of occurrence, 637
germination and toxin production in infant intestine, 614
presence in honey, soil, vacuum cleaner dust, 652
type A and type B strains, characteristics and occurrence, 637, 642
see also Botulism
Clostridium difficile
causing antibiotic-associated colitis in hamsters and humans, effect of antibiotic treatment, 386
cytotoxin, partial purification and characterization, 379, 727
in antibiotic-associated pseudomembraneous colitis, 370, 530

Clostridium perfringens, virulence factors, review, 254
Clostridium species, lower anticlostridial activity of cefoxitin than of parenterally administered cephalosporins except against *C. perfringens*, 218
Coccal infections, in relation to hemorrhagic disease, 571
Colitis, antibiotic-associated
in hamsters and humans, effects of antibiotics on *C. difficile*, 386
pseudomembranous, due to *C. difficile*, review, 530
treatment with vancomycin, 370
Complement
alternative pathway components, presence required in normal human serum for opsonization of *B. fragilis* and *B. thetaiotaomicron*, 347
role in host defense and inflammation, review, 483
Cytomegalovirus, murine, effects of infection on immune response to tumor allograft, 967
Cytotoxin, from *C. difficile*, partial purification and characterization, 379
Deficiency, genetic, of complement components, clinical signs and symptoms, alternative host defense mechanisms, 483
Diabetes mellitus, cefoxitin treatment of foot infections due to mixed anaerobic flora in diabetics, 210
Encephalomyelitis
acute disseminated and experimental allergic, prototypic autoimmune diseases, 468
experimental allergic, potentiation in rats by persistent central nervous system infection with defective measles virus, 468
Endocarditis
bacterial, mixed results of cefoxitin treatment, 170
viridans streptococcal, role of various species including pyridoxal-dependent streptococci, 955
Enterobacteriaceae, grown in presence of subminimal inhibitory concentration of ampicillin or mecillinam, effect of serum and blood, 797
Enterotoxins, from *V. cholerae* and *E. coli*, modes of action, review, 918
Enzymes, of anaerobic bacteria, review, 248
Epidemiology
of acute glomerulonephritis following streptococcal pyoderma, 935
of infant botulism, U. S. (1975–1978), 642
of nosocomial infections
due to *Klebsiella* and other gram-negative bacilli, 736
due to *P. pseudomallei*, 891
due to *Klebsiella* and other gram-negative bacilli, 736
of streptococcal infections, changes, 967
Epstein-Barr virus, possible role in rheumatoid arthritis, 997
Escherichia coli
antibiotic-inactivating enzymes, and growth in subminimal inhibitory concentrations of antibiotics, 852
attachment to human cells in vitro, effects of subminimal inhibitory concentrations of antibiotics, 832, 838, 845
enterotoxin, mode of action, 918
K88 antigen, role in bacterial adherence to specific membrane receptors in proximal intestine, 517
tolerance of oxygen-sensitive mutants to superoxide, hydrogen peroxide, and oxygen, 357
Flora, intestinal, role in resistance to infant botulism, 668
Foot infections, due to mixed anaerobic flora, in diabetics, treatment with cefoxitin, 210
Fosfomycin, subminimal inhibitory concentration, effect on immune response induced by treated bacteria, 858
Fusobacterium species, human antibody response, summary of current data, 337
Gasser's syndrome, 571
Genetic determinants of antibiotic resistance, 55
Glomerulonephritis, acute, following streptococcal pyoderma, epidemiology, review, 935
Gram-negative bacteria, causing meningitis, treatment of infection with cefoxitin, 134
Gram-negative bacilli, and *Klebsiella*; as cause of nosocomial infections, 736
Gram-negative rods, endemic, multiply resistant, treatment of infection with cefoxitin, 175
Granulomatous synovitis, role of mycobacteria, 729
Gynecologic and obstetric infections, treatment with cefoxitin, 199, 202
Hemolysis, of guinea pig erythrocytes, by plasma and urine of *L. pneumophila*-infected rabbits, 912
Hemorrhagic fevers, with special reference to Southern Africa, 571
Henoch-Schönlein purpura, 571
Immune globulins, human-derived, for treatment of botulism, 689
Immune response
induced by bacteria treated with subminimal inhibitory concentrations of fosfomycin, variability, 858
to tumor allograft, effect of murine cytomegalovirus infection, 976
Immunity, prolonged, of whooping cough, "pertussis toxin" as cause, 401
Immunoglobulin, presence required in normal human serum for opsonization of *B. fragilis* and *B. thetaiotaomicron*, 347
Infant botulism, *see under* Botulism
Infection, nosocomial, due to *P. pseudomallei*, case reports and epidemiology, 891
Infections, experimental, effects of subminimal inhibitory concentrations of antibiotics, 862
Inflammation, complement-mediated, result of complement activation in abnormal circumstances, 483
Influenza A virus, wild-type, comparison of five strains in ferret tracheal organ culture, 946
Influenza viruses
and human respiratory tract, 592
recombination and evolution, study of ducks in Hong Kong, hypothesis, 885
Joseph E. Smadel Memorial Lecture, 468
Klebsiella, epidemiology, and hospital-associated infections, 736
Lassa fever, 571
Legionella pneumophila, hemolytic activity in plasma and urine of infected rabbits, 912
Lipopolysaccharide, of *B. fragilis*, chemotactic for polymorphonuclear leukocytes, 342
Live virus vaccines, rationale for continued use of temperature-sensitive mutants, 413
Malaria, adherence of *P. knowlesi* to specific receptors on erythrocyte membranes, 517
Marburg virus disease, 571
Maxwell Finland lectures, 502, 592

Mecillinam
effect of subminimal inhibitory concentrations on DNA, RNA, and protein synthesis of *S. typhimurium*, 813
or ampicillin, Enterobacteriaceae grown in presence of subminimal inhibitory concentration, effect of serum and blood, 797
Membrane receptors, specific, pathogenetic and therapeutic implications in infectious diseases, 517
Meningitis
due to antibiotic-resistant *E. coli* or *K. pneumoniae*, treatment with cefoxitin, 134
due to *S. aureus*, in dogs, effect on penetration of cefoxitin into cerebrospinal fluid, 132
Metronidazole, activity against *E. coli* dependent on presence of anaerobe, 291
M types of *Streptococcus* in acute glomerulonephritis following pyoderma or pharyngitis, 935
Multiple sclerosis, prototypic chronic demyelinating process, immunologic events shared with experimental allergic and acute disseminated encephalomyelitis, 468
Murein hydrolases, and autolytic activity triggered in β-lactam-treated cells, 434
Mycobacteria, atypical, role in granulomatous synovitis, 729
Mycoplasma pneumoniae, longitudinal study of pathogenesis in children at a day care center, 1007
Myelin basic protein, role in neuroimmunologic disease, 468
Myeloma proteins, antibodies to streptococcal carbohydrates as substitutes in studies of antibody molecular structure, review, 904
Neisseria gonorrhoeae, comparison of cefoxitin with penicillin for treatment of urethritis, 183
Neuroimmunologic diseases, of animals and humans, history, current data, new perspectives, 468
Nitrofurantoin, effects of subminimal inhibitory concentrations on attachment of *E. coli* to human uroepithelial cells in vitro, 838
Nucleic acid and protein synthesis, in *S. typhimurium*, effect of subminimal inhibitory concentrations of mecillinam, 813
Obstetric and gynecologic infections, treatment with cefoxitin, 199, 202
Opsonization, of *B. fragilis* and *B. thetaiotaomicron*, by normal human serum, role of immunoglobulin and alternative complement pathway components, 347
Orthopedic patients, treatment of infections with cefoxitin, 207
Osteomyelitis
contiguous, efficacy of cefoxitin treatment, 165
pyogenic vertebral, case reports and review, 754
Penetration, of cefoxitin and cephalothin, into *B. fragilis*-infected sites, 106
Penetration, of cefoxitin
into canine cerebrospinal fluid, effect of *S. aureus* meningitis, 132
into human cerebrospinal fluid, 127, 134
Penicillin
compared with cefoxitin for treatment of uncomplicated gonococcal urethritis, 183
mechanism of action, 787
possible modes of action, review, 434
Penicillin-binding proteins
intracellular functions, 434
role in action of β-lactam antibiotics, 39, 434
Penicillium, work of Theodor Billroth, history, 880
Periodontal infections, role of *B. melaninogenicus* and other anaerobes, 313
Pertussis toxin, proposed designation for *B. pertussis* antigen causing harmful effects and prolonged immunity of whooping cough, 401; erratum, 897
Pertussis vaccine, role in decline of pertussis-related mortality in U.S., 927
Pharmacokinetics, of cefoxitin
in patients with renal insufficiency, 118 [726], 189
vs. cephalosporins, 90
Plague, medieval, evidence for transmission by human flea, 563
Plasmids, genetic determinants of antibiotic resistance, 55
Plasmodium knowlesi, adherence to specific receptors on erythrocyte membranes, 517
Pneumonia, influenzal, 592
Poliomyelitis, summary of experience with vaccine, 502
Polysaccharide
capsular, of *B. fragilis*, virulence factor causing abscess formation in intraabdominal sepsis model, 278
streptococcal, group A-variant, chemical composition as explanation of difficulty of preparation of precipitating antisera, review, 904
Protein and nucleic acid synthesis, in *S. typhimurium*, effect of subminimal inhibitory concentrations of mecillinam, 813
Pseudomonas pseudomallei, nosocomial infections, epidemiology, 891
Pulmonary function, alterations caused by influenza, 592
Pyoderma, streptococcal, preceding acute glomerulonephritis, epidemiology, review, 935
Pyridoxal-dependent streptococci, agents of culture-negative endocarditis, 955
"Pyroplasmosis hominis," classic description of Rocky Mountain spotted fever (reprint of Wilson and Chowning, 1904), 540
Q fever, 571
Rammelkamp, Charles H., Jr.
biography, 899
symposium, 904–1015
Receptors, specific membrane, pathogenetic and therapeutic implications in infectious diseases, 517
Recombination, and evolution of influenza viruses, study of ducks in Hong Kong, hypothesis, 885
Renal insufficiency, effect on pharmacokinetics of cefoxitin, 118 [726], 189
Resistance
to antibiotics
emergence in hospitals (1935–1975), 4
general mechanisms, 23
genetic determinants, 55
to infant botulism, role of intestinal flora, 668
Respiratory syncytial virus, longitudinal study of pathogenesis in children at a day care center, 1007
Respiratory tract
disease due to respiratory syncytial virus and *M. pneumoniae*, longitudinal study of pathogenesis in children at a day care center, 1007
human, and influenza viruses, 592
infections, efficacy of cefoxitin treatment, 158
Rheumatoid arthritis, possible role of Epstein-Barr virus, 997

Rickettsial infections, 571
Rift Valley fever, 571
Rocky Mountain spotted fever
  and babesiosis, comment on work of Wilson and Chowning, 895
  classic description (reprint of Wilson and Chowning, 1904), 540
  review of classic description by Wilson and Chowning, 559
Rubella, summary of experience with vaccine, 502
Salmonella, value of control program, 600
Streptococcal polysaccharides, chemical nature, review, 904
Streptococcal pyoderma, preceding acute glomerulonephritis, epidemiology, review, 935
Streptococcus
  group A, changing concepts in biology of organism and epidemiology of infections, 967
  viridans group, role of various species (including pyridoxal-dependent streptococci) in endocarditis, 955
Sudden infant death syndrome, relation to infant botulism, 614, 630
Surgical patients, use of cefoxitin, 195
Taxonomy, of anaerobic bacteria, review, 248
Temperature-sensitive phenotype
  as possible direct cause of viral attenuation, 413
  association with viral attenuation in animals and humans, implications for live virus vaccines, 413
Temperature-sensitive virus
  mutant, experimental infection of animals and humans, 413
  naturally occurring, human experience, 413
  rationale for continued use in live virus vaccines, 413
Tick-bite fever, of Southern Africa, 571
Tolerance, to β-lactam antibiotics, possible mechanisms, 434
Toxin, botulinal, *see* Botulinal toxin
Toxin, pertussis, proposed designation for *B. pertussis* antigen causing harmful effects and prolonged immunity of whooping cough, 401
Triggering model, for mode of action of β-lactam antibiotics against pneumococci, 434
Salmonella typhimurium, effect of subminimal inhibitory concentrations of mecillinam on nucleic acid and protein synthesis, 813
Salmonella wien, treatment with subminimal inhibitory concentrations of fosfomycin, variability of induced immune response, 858
Scarlatina, classic summation of interrelations among scarlet fever, sore throat, rheumatic fever, and renal function disturbances (reprint of Trousseau, 1873), 1016
Seal finger, case study, 567
Sepsis, intraabdominal
  due to mixed aerobic-anaerobic flora, rat model, 291
  efficacy of parenteral antibiotics for treatment, 302
Septicemia
  plague, meningococcal, staphylococcal, streptococcal, 571
  treatment with cefoxitin, 189
Shigella toxin, nature of binding to specific membrane receptors, comparison with binding of cholera toxin, 517
Sindbis fever, 571
Single target-unbalanced growth, "old" model for mode of action of β-lactam antibiotics, 434
Skin infections, efficacy of cefoxitin treatment, 165
Soft tissue infections, efficacy of cefoxitin treatment, 165
Southern Africa, recent outbreaks of hemorrhagic fevers, 571
Staphylococcus aureus, antibiotic-inactivating enzymes, and growth in subminimal inhibitory concentrations of antibiotics, 852
Streptococcal carbohydrates, antibodies, as substitutes for myeloma proteins in studies of antibody molecular structure, review, 904
Streptococcal group A-variant polysaccharide, chemical composition as explanation of difficulty of preparation of precipitating antisera, review, 904
Trypanosomiasis, 571
Urethritis, uncomplicated, due to *N. gonorrhoeae*, cefoxitin vs. penicillin treatment, 183
Vaccine, pertussis, role in decline of pertussis-related mortality in U.S., 927
Vaccines, viral
  live virus, rationale for continued use of temperature-sensitive mutants, 413
  summary of experience with poliomyelitis and rubella vaccines, 502
Vancomycin, for treatment of antibiotic-associated pseudomembranous colitis induced by *C. difficile*, 370
Vibrio cholerae
  enterotoxin, mode of action, 918
  nature of binding of cholera toxin to specific membrane receptors, comparison with binding of shigella toxin, 517
Viperine snakebite, 571
Viridans streptococci, role of various species in endocarditis, 955
Virulence factors
  of anaerobic bacteria
    overview, 246
    summary of symposium, 398
    symposium, 245–400
  of *B. fragilis*, capsular polysaccharide as cause of abscess formation in intraabdominal sepsis model, 278
  of *C. perfringens*, review, 254
Virus, temperature-sensitive
  mutant, experimental infection of animals and humans, 413
  naturally occurring, human experience, 413
  rationale for continued use in live virus vaccines, 413
West Nile fever, 571
Whooping cough, "pertussis toxin" as cause of harmful effects and prolonged immunity, 401
Wound infection, due to mixed aerobic-anaerobic flora, rat model, 291
Yellow fever, 571
Yersinia pestis, medieval epidemics of infection, evidence for transmission by human flea, 563

FILMED

Reviews of Infectious Diseases

An Official Publication of the Infectious Diseases Society of America

Edward H. Kass, *Editor*
John R. David, *Associate Editor*
Alice S. Huang, *Associate Editor*
Dennis L. Kasper, *Associate Editor*
Jerome O. Klein, *Associate Editor*

Mary M. Eichhorn Adams, *Assistant Editor*
Nancy Kurz Voynow, *Managing Editor*
Abbe-Ann Levine, *Editorial Assistant*
Julie McCoy, *Editorial Assistant*
Penelope Staples, *Editorial Assistant*

EDITORIAL BOARD

Robert Austrian, Philadelphia, Pa.
Michael M. Frank, Bethesda, Md.
D. Carleton Gajdusek, Bethesda, Md.
Sherwood L. Gorbach, Boston, Mass.
King K. Holmes, Seattle, Wash.
Harold Jennings, Ottawa, Canada

Richard T. Johnson, Baltimore, Md.
Samuel L. Katz, Durham, N.C.
Thomas C. Merigan, Jr., Stanford, Calif.
Kenneth Warren, New York, N.Y.
Frank E. Young, Rochester, N.Y.

INTERNATIONAL BOARD OF EDITORS

Jacques F. Acar, Paris, France
Lawrence R. Freedman, Lausanne, Switzerland
Ralph van Furth, Leiden, The Netherlands
C. H. Huang, Peking, China
Lars O. Kallings, Stockholm, Sweden
Jean Klastersky, Brussels, Belgium

P. Helena Mäkelä, Helsinki, Finland
Francis O'Grady, Nottingham, England
Theodore Sacks, Jerusalem, Israel
David A. J. Tyrrell, London, England
Yuichi Yamamura, Osaka, Japan

Volume 1
January–December 1979

All rights reserved

THE UNIVERSITY OF CHICAGO PRESS, CHICAGO
THE UNIVERSITY OF CHICAGO PRESS LTD., LONDON, S.W. 1
© 1979 BY THE UNIVERSITY OF CHICAGO
PUBLISHED BIMONTHLY JANUARY-DECEMBER
Printed in U.S.A.

Reviews of Infectious Diseases

Volume 1 • *January-February 1979* • *Number 1*

Contents

Editorial: The *Reviews*. EDWARD H. KASS 1

Introduction. EDWARD H. KASS and DENIS A. EVANS 2

Session I

Emergence of Antibiotic Resistance in Hospitals, 1935–1975. MAXWELL FINLAND 4

Discussion 22

General Mechanisms of Antimicrobial Resistance. JULIAN DAVIES 23

Discussion 28

β-Lactam Antibiotics and β-Lactamases: Two Sides of a Continuing Story. M. H. RICHMOND 30

Discussion 37

Session II

Mode of Action of β-Lactam Antibiotics. D. J. TIPPER 39

Discussion 54

Session III

Genetic Determinants of Microbial Resistance to Antibiotics. FRANK E. YOUNG and LEONARD MAYER 55

Discussion 63

The Design of New Drugs That Resist Microbial Inactivation. B. G. CHRISTENSEN, L. J. RUSWINKLE, and L. D. CAMA 64

Cefoxitin and Cephamycins: Microbiological Studies. EDWARD O. STAPLEY, JEROME BIRNBAUM, A. KATHRINE MILLER, HYMAN WALLICK, DAVID HENDLIN, and H. BOYD WOODRUFF 73

Discussion 88

Session IV

Pharmacokinetics and Comparative Pharmacology of Cefoxitin and Cephalosporins. J. J. SCHROGIE, J. D. ROGERS, K. C. YEH, R. O. DAVIES, G. I. HOLMES, H. SKEGGS, and C. M. MARTIN 90

Discussion 98

A Glimpse of the Early History of the Cephalosporins. E. P. ABRAHAM 99

Session V

Penetration of Cephalothin and Cefoxitin into Experimental Infections with *Bacteroides fragilis*. J. PAUL O'KEEFE, FRANCIS P. TALLY, MICHAEL BARZA, and SHERWOOD L. GORBACH 106

Discussion 112

Cefoxitin for Treatment of Infections Due to Anaerobic Bacteria. BARBARA D. KIRBY, DAVID F. BUSCH, DIANE M. CITRON, and SYDNEY M. FINEGOLD 113

Discussion 117

Pharmacokinetics of Cefoxitin in Normal Subjects and in Patients with Renal Insufficiency. G. HUMBERT, J. P. FILLASTRE, A. LEROY, M. GODIN, and C. VAN WINZUM 118

Discussion 126

Penetration of Cefoxitin into Human Cerebrospinal Fluid: Comparison with Cefamandole, Ampicillin, and Penicillin. CHIEN LIU, DANIEL R. HINTHORN, GLEN R. HODGES, JANE L. HARMS, GUILLERMO COUCHONNAL, and L. DWORZACK 127

Penetration of Cefoxitin into Cerebrospinal Fluid of Dogs with and without Experimental Meningitis. P. MASSIP, M. D. KITZIS, V. T. TRAN, M. J. ARMENGAUD, and M. ARMENGAUD .. 132

Penetration of Cefoxitin into Cerebrospinal Fluid and Treatment of Meningitis Caused by Gram-Negative Bacteria. S. RAMACHANDRAN NAIR, CHARLES E. CHERUBIN, and MARTIN WEINSTEIN 134

Discussion 142

Session VI

Comparative Studies of Cefoxitin and Cephalothin: An Overview. HAROLD C. NEU 144

Discussion 151

Treatment of Significant Bacterial Infections in Adults with Cefoxitin. BRUCE S. RIBNER, BARBARA S. BILLIARD, and EARL H. FREIMER 152

Clinical Evaluation of Cefoxitin in the Treatment of Respiratory Tract and Other Acute Bacterial Infections. MELVIN P. WEINSTEIN and THEODORE C. EICKHOFF 158

Therapy of Skin, Soft Tissue, and Bone Infections with Cefoxitin Sodium. ROBERT L. PERKINS, THOMAS G. SLAMA, ROBERT J. FASS, RICHARD B. PRIOR, JOSEPH F. PLOUFFE, JOHN F. WARNER, and THOMAS M. FILE 165

Cefoxitin Therapy for Bacterial Endocarditis. DAVID WEBB, HARAGOPAL THADEPALLI, and VINH BACH 170

Infections Due to Endemic, Multiply Resistant Gram-Negative Rods: Sensitivity to and Therapy with Cefoxitin. ROBERT H. ALFORD 175

Treatment of Uncomplicated Gonococcal Urethritis with Cefoxitin: Comparison with Penicillin. MARTIN S. SIEGEL, SUMNER E. THOMPSON, PETER L. PERINE, STUART T. BROWN, GLADYS REYNOLDS, and CLYDE THORNSBERRY 183

Discussion 188

Session VII

Treatment of Septicemic Patients with Cefoxitin: Pharmacokinetics in Renal Insufficiency. GEORGE J. PAZIN, STANLEY N. SCHWARTZ, MONTO HO, JAMES A. LYON, and A. WILLIAM PASCULLE 189

Cefoxitin Therapy for Surgical Patients. WILLIAM M. RAMBO, VICTOR E. DEL BENE, and DIANE K. DELAMAR 195

Cefoxitin in Obstetric and Gynecologic Infections. WILLIAM J. LEDGER and DANIEL SMITH ... 199

Cefoxitin in Treatment of Obstetric and Gynecologic Infections. RICHARD L. SWEET, MARILYN ROBBIE, and KEITH HADLEY 202

Discussion 205

Session VIII

Clinical Evaluation of Cefoxitin in Treatment of Infections in 47 Orthopedic Patients. DAVID J. SCHURMAN and MICHAEL DILLINGHAM 206

The Fetid Foot: Lower-Extremity Infections in Patients with Diabetes Mellitus. JOSHUA FIERER, DALE DANIEL, and CHARLES DAVIS 210

In Vitro Activity of Cefoxitin and Parenterally Administered Cephalosporins against Anaerobic Bacteria. VERA L. SUTTER, BARBARA KIRBY, and SYDNEY M. FINEGOLD 218

Intramuscular Cefoxitin. RICHARD V. MCCLOSKEY 224

Safety of Cefoxitin: An Approach to the Analysis of Laboratory Data. KENNETH R. BROWN, ALBERT J. GETSON, A. LAWRENCE GOULD, CHRISTOPHER M. MARTIN, and FRANCIS M. RICCI .. 228

Discussion 232

Cefoxitin: An Overview of Clinical Studies in the United States. HAROLD C. NEU 233

Statement of Editorial Policy and Instructions to Authors 240

Volume 1 • *March-April 1979* • *Number 2*

Contents

Participants 245

Virulence Factors of Anaerobic Bacteria: An Overview. DENNIS L. KASPER 246

Session I

Taxonomy, Enzymes, and Clinical Relevance of Anaerobic Bacteria. SYDNEY M. FINEGOLD .. 248

Discussion 253

Virulence Factors of *Clostridium perfringens.* LOUIS DS. SMITH 254

Discussion 261

Immunochemical Characterization of Surface Antigens of *Bacteroides melaninogenicus.* BERNARD J. MANSHEIM, ANDREW B. ONDERDONK, and DENNIS L. KASPER 263

Discussion 276

Surface Antigens as Virulence Factors in Infection with *Bacteroides fragilis.* DENNIS L. KASPER, ANDREW B. ONDERDONK, B. FRANK POLK, and JOHN G. BARTLETT 278

Discussion 289

Session II

Experimental Animal Models for Anaerobic Infections. A. B. ONDERDONK, D. L. KASPER, B. J. MANSHEIM, T. J. LOUIE, S. L. GORBACH, and J. G. BARTLETT 291

Efficacy of Parenteral Antibiotics in the Treatment of Experimentally Induced Intraabdominal Sepsis. RONALD LEE NICHOLS, JEFFREY W. SMITH, ELWYN N. FOSSEDAL, and ROBERT E. CONDON 302

Discussion 310

The Role of *Bacteroides melaninogenicus* and Other Anaerobes in Periodontal Infections. MICHAEL G. NEWMAN 313

Discussion 324

Bacteriophages of *Bacteroides*. S. J. BOOTH, R. L. VAN TASSELL, J. L. JOHNSON, and T. D. WILKINS 325

Discussion 335

Antibody Response to Anaerobic Bacteria. ALEX C. SONNENWIRTH 337

Discussion 341

Session III

The Chemotactic Effect of *Bacteroides fragilis* Lipopolysaccharide. TOR HOFSTAD and KJELL SVEEN 342

Discussion 346

Participation of Immunoglobulin and the Alternative Complement Pathway in Opsonization of *Bacteroides fragilis* and *Bacteroides thetaiotaomicron*. ANN B. BJORNSON and H. STEPHEN BJORNSON 347

Discussion 356

Superoxide, Hydrogen Peroxide, and Oxygen Tolerance of Oxygen-Sensitive Mutants of *Escherichia coli*. H. MOUSTAFA HASSAN and IRWIN FRIDOVICH 357

Discussion 368

Colitis Induced by *Clostridium difficile*. JOHN G. BARTLETT, TEWEN CHANG, NANCY S. TAYLOR, and ANDREW B. ONDERDONK 370

Partial Purification and Characterization of a Cytotoxin from *Clostridium difficile*. Nancy S. TAYLOR and JOHN G. BARTLETT 379

Antibiotic-Associated Colitis: Effects of Antibiotics on *Clostridium difficile* and the Disease in Hamsters. ROBERT FEKETY, JOSEPH SILVA, RENU TOSHNIWAL, MARIA ALLO, JOHN ARMSTRONG, ROBERT BROWNE, JOHN EBRIGHT, and GARY RIFKIN 386

Discussion 397

Virulence Factors of Anaerobic Bacteria: Summary of the Symposium. JOHN G. BARTLETT and ANDREW B. ONDERDONK 398

Volume 1 • *May–June 1979* • *Number 3*

Contents

Review Articles

Pertussis Toxin: The Cause of the Harmful Effects and Prolonged Immunity of Whooping Cough. A Hypothesis. MARGARET PITTMAN 401

The Association of the Temperature-Sensitive Phenotype with Viral Attenuation in Animals and Humans: Implications for the Development and Use of Live Virus Vaccines. DOUGLAS D. RICHMAN and BRIAN R. MURPHY 413

From Penicillin-Binding Proteins to the Lysis and Death of Bacteria: A 1979 View. ALEXANDER TOMASZ 434

Neuroimmunologic Diseases of Animals and Humans. The Joseph E. Smadel Memorial Lecture. PHILIP Y. PATERSON 468

The Complement System in Host Defense and Inflammation. MICHAEL M. FRANK 483

Viral Vaccines and Their Ways. The Maxwell Finland Lecture. DOROTHY M. HORSTMANN 502

Specific Membrane Receptors: Pathogenetic and Therapeutic Implications in Infectious Diseases. GERALD T. KEUSCH 517

Antibiotic-Associated Pseudomembranous Colitis. JOHN G. BARTLETT 530

Classics in Infectious Diseases

Studies in Pyroplasmosis Hominis ("Spotted Fever" or "Tick Fever" of the Rocky Mountains). LOUIS B. WILSON and WILLIAM M. CHOWNING 540

A Review: "Studies in Pyroplasmosis Hominis ('Spotted Fever' or 'Tick Fever' of the Rocky Mountains)." RICHARD A. ORMSBEE 559

Historical Article

Some Evidence for Interhuman Transmission of Medieval Plague. STEPHEN R. ELL 563

Case Study

Seal Finger. RICHARD B. MARKHAM and B. FRANK POLK 567

Volume 1 • *July–August 1979* • *Number 4*

Contents

Review Articles

Hemorrhagic Fevers, with Special Reference to Recent Outbreaks in Southern Africa. J. H. S. GEAR 571

The Influenza Viruses and the Human Respiratory Tract. The Maxwell Finland Lecture. CHARLES H. STUART-HARRIS 592

Are We Ready for a National Salmonella Control Program? H. GRAHAM PURCHASE 600

A Seminar on Infant Botulism

Participants 611

Introduction. ROGER A. FELDMAN 612

Clinical Characteristics

The Clinical Spectrum of Infant Botulism. STEPHEN S. ARNON and JAMES CHIN 614

Discussion 622

Differential Diagnosis of Infant Botulism. LAWRENCE W. BROWN 625

Discussion 629

The Sudden Infant Death Syndrome and Infant Botulism. DONALD R. PETERSON, MELVIN W. EKLUND, and NINA M. CHINN 630

Discussion 635

Epidemiologic Characteristics

Clostridium botulinum: Characteristics and Occurrence. LOUIS DS. SMITH 637

Discussion 640

Epidemiologic Characteristics of Infant Botulism in the United States, 1975–1978. ROBERT A. GUNN 642

Discussion 646

Laboratory Study

Laboratory Procedures for Cases of Suspected Infant Botulism. CHARLES L. HATHEWAY 647

Discussion 651

Laboratory Aspects of Infant Botulism in California. THADDEUS F. MIDURA 652

Discussion 655

Pathogenesis

The Action of Botulinal Toxin. LANCE L. SIMPSON 656

Discussion 660

Absorption of Botulinal Toxin from the Gastrointestinal Tract. PETER F. BONVENTRE 663

The Intestinal Flora and Infant Botulism. DAVID J. HENTGES 668

Discussion 672

Processes of Transport and Absorption in the Developing Infant Intestine. CAROL M. SCHILLER and RAMSEY WALDEN 674

Discussion 681

Animal Models for the Study of Infant Botulism. HIROSHI SUGIYAMA 683

Discussion 688

Treatment

Human-Derived Immune Globulins for the Treatment of Botulism. JOSEPH F. METZGER and GEORGE E. LEWIS, JR. 689

Discussion 691

Prevention

Food and Environmental Aspects of Infant Botulism in California. JAMES CHIN, STEPHEN S. ARNON, and THADDEUS F. MIDURA 693

Discussion 697

Summary: Current Perspectives and Priorities for Research in Infant Botulism. JOHN D. NELSON 698

Classics in Infectious Diseases

A New Anaerobic Bacillus and Its Relation to Botulism. E. VAN ERMENGEM 701

Botulism: From van Ermengem to the Present. A Comment. ROBERT A. GUNN 720

From the Center for Disease Control

Botulism in the United States—1977. ROBERT A. GUNN and WILLIAM A. TERRANOVA 722

Correspondence

Pharmacokinetics of Cefoxitin. SCOTT L. TRAUB 726

Reply. J. P. FILLASTRE 726

Erratum (Taylor, N. S., Bartlett, J. G., 1:379–385) 727

Volume 1 • *September-October 1979* • *Number 5*

Contents

Review Articles

Granulomatous Synovitis: The Role of Atypical Mycobacteria. WILLIAM L. SUTKER, L. LEE LANKFORD, and RALPH TOMPSETT 729

Epidemiology of *Klebsiella* and Hospital-Associated Infections. JOHN Z. MONTGOMERIE 736

Pyogenic Vertebral Osteomyelitis: Report of Nine Cases and Review of the Literature. FRANCISCO L. SAPICO and JOHN Z. MONTGOMERIE 754

Significance of Subminimal Inhibitory Concentrations of Antibiotics: A Symposium

Participants 780

The Effects and Significance of Subminimal Inhibitory Concentrations of Antibiotics. JOHN A. WASHINGTON II 781

Does Penicillin Kill Bacteria? G. D. SHOCKMAN, L. DANEO-MOORE, J. B. CORNETT, AND M. MYCHAJLONKA 787

Effect of Serum and Blood on Enterobacteriaceae Grown in the Presence of Subminimal Inhibitory Concentrations of Ampicillin and Mecillinam. VICTOR LORIAN and BARBARA A. ATKINSON 797

Interactions Between Antibacterial Drugs Below the Minimal Inhibitory Concentration. DAVID GREENWOOD 807

Effect of Subminimal Inhibitory Concentrations of Mecillinam on the Synthesis of DNA, RNA, and Protein of *Salmonella typhimurium*: A Proposed Mechanism of Action. LEONARD AMARAL 813

Range of Antibacterial Activity of Antibiotics at Subminimal Inhibitory Concentrations: The Ratio of Minimal Inhibitory Concentration to Minimal Antibiotic Concentration. L. EZROW, C. SACEANU, and H. DABYDEEN 821

Recovery Period and the Exposure of Bacteria to Subminimal Inhibitory Concentrations of Antibiotics. MARIE-DOMINIQUE KITZIS, DANIEL H. BOUANCHAUD, and JACQUES F. ACAR 825

Suppression of Bacterial Adherence by Subminimal Inhibitory Concentrations of β-Lactam and Aminoglycoside Antibiotics. ITZHAK OFEK, EDWIN H. BEACHEY, BARRY I. EISENSTEIN, MICHAEL L. ALKAN, and NATHAN SHARON 832

Effects of Subminimal Inhibitory Concentrations of Ampicillin, Chloramphenicol, and Nitrofurantoin on the Attachment of *Escherichia coli* to Human Uroepithelial Cells in Vitro. TORSTEN SANDBERG, KARIN STENQVIST, and CATHARINA SVANBORG-EDÉN 838

Effects of Antibiotics at Concentrations Below the Minimal Inhibitory Concentration on the Adhesiveness of *Escherichia coli* in Vitro. KLAUS VOSBECK, HANS HANDSCHIN, EVA-BRIGITTE MENGE, and O. ZAK 845

Drug-Inactivating Enzymes of Bacteria Grown in Subminimal Inhibitory Concentrations of Antibiotics. G. GIALDRONI GRASSI 852

Variability of Immune Response Induced by Bacteria Treated with Subminimal Inhibitory Concentrations of Fosfomycin. I. VIANO, P. MARTINETTO, A. VALTZ, M. SANTIANO, and S. BARBARO 858

Effects of Subminimal Inhibitory Concentrations of Antibiotics in Experimental Infections. O. ZAK and F. KRADOLFER 862

Historical Article

Billroth and *Penicillium*. GUIDO MAJNO and ISABELLE JORIS 880

Hypothesis

Recombination as a Mechanism in the Evolution of Influenza Viruses: A Two-Year Study of Ducks in Hong Kong. I. D. GARDNER and K. F. SHORTRIDGE 885

Case Study

Nosocomial Infection Due to *Pseudomonas pseudomallei:* Two Cases and an Epidemiologic Study. LESLIE R. ASHDOWN 891

Correspondence

Spotted Fever and Babesiosis. ROBERT L. PINSKY and LARRY I. LUTWICK 895

Notices 896

Erratum (Pittman, M., 1:401–412) 897

Volume 1 • *November–December 1979* • *Number 6*

Contents

Biography of Charles H. Rammelkamp, Jr. HAROLD B. HOUSER 899

Charles H. Rammelkamp, Jr.: Curriculum Vitae 901

Symposium Participants 903

Symposium Articles

Antibodies to Streptococcal Carbohydrate: Substitutes for the Myeloma Proteins. RICHARD M. KRAUSE and JOHN E. COLIGAN 904

Discussion 911

Hemolytic Activity of Plasma and Urine from Rabbits Experimentally Infected with *Legionella pneumophila*. WILLIAM B. BAINE, J. KAMILE RASHEED, H. WILLIAM MACA, and ARNOLD F. KAUFMANN 912

Discussion 917

Modes of Action of Enterotoxins from *Vibrio cholerae* and *Escherichia coli*. MICHAEL FIELD . 918

Discussion 926

An Evaluation of Pertussis Vaccine. EDWARD A. MORTIMER, JR., and PAUL K. JONES 927

Discussion 933

Post-streptococcal Glomerulonephritis Following Pyoderma. HUGH C. DILLON, JR. 935

Discussion 944

Comparison of Several Wild-Type Influenza Viruses in the Ferret Tracheal Organ Culture System. CHARLES H. HOKE, JR., JANET A. HOPKINS, GORDON MEIKLEJOHN, and STEVEN R. MOSTOW 946

Discussion 953

Viridans Streptococcal Endocarditis: The Role of Various Species, Including Pyridoxal-Dependent Streptococci. RICHARD B. ROBERTS, ARLENE G. KRIEGER, NEAL L. SCHILLER, and KATHARINE C. GROSS 955

Discussion 966

Changes and Changing Concepts in the Biology of Group A Streptococci and in the Epidemiology of Streptococcal Infections. LEWIS W. WANNAMAKER 967

Discussion 974

Effects of Murine Cytomegalovirus Infection on the Immune Response to a Tumor Allograft. JOHN D. HAMILTON, JAMES F. FITZWILLIAM, K. S. CHEUNG, and DAVID J. LANG 976

Discussion 987

Rheumatic Fever, Rheumatic Heart Disease, and the Streptococcal Connection: The Role of Streptococcal Antigens Cross-Reactive with Heart Tissue. MELVIN H. KAPLAN 988

Discussion 996

The Possible Role of Epstein-Barr Virus in Rheumatoid Arthritis. ENG M. TAN 997

Discussion 1006

The Longitudinal Approach to the Pathogenesis of Respiratory Disease. FLOYD W. DENNY, WALLACE A. CLYDE, JR., ALBERT M. COLLIER, GERALD W. FERNALD, and FRED W. HENDERSON 1007

Discussion 1014

Classics in Infectious Diseases

Scarlatina. A. TROUSSEAU 1016

Notices 1027

Erratum (Participants, 1:611) 1028

Reviewers for Volume 1 1029

Index to Volume 1 1031